Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen
Status:
Terminated
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
This was a Phase 1 dose-escalation study of CMD-193, a humanized monoclonal antibody linked
to the toxin calicheamicin, in subjects with advanced tumors expressing the Lewis-Y antigen.
The primary study objective was to determine the biodistribution and pharmacokinetics (PK) of
111-In-CMD-193 (i.e., CMD-193 tagged with a small amount of radioactive Indium [111-In]),
with secondary objectives of determining changes in tumor metabolism and describing the
antitumor responses to CMD-193.